You are here: Home » Archives for Law/Legal Issues

Dmitry Shubov Outlines New Strategic U.S. Commercial Law Readiness for Southeast Asian Asset Tokenization Startups

FREMONT, Calif., April 17, 2026 (GLOBE NEWSWIRE) — In the wake of the new 2026 Sidley Blockchain Bulletin, which highlights tokenized Real-World Assets (RWAs) as the next frontier for capital markets, Dmitry Shubov Consulting is releasing a new strategic analysis focused on the “compliance gap” hitting Southeast Asian (SEA) startups. With the June 3, 2026, New York UCC Article 12 rollout just around the corner, the briefing delves into the new “exclusive control” rules that these firms must meet if they want to turn their digital assets into legitimate collateral for U.S. bank financing.

Industry leaders identify three critical frictions currently stalling SEA expansion:

  • The Control Standard Hurdles: The biggest wall for cross-border expansion right now is getting digital architecture to play nice with UCC Article 12's “Control” rules. If an SEA startup can’t prove the “exclusive power” required by these new amendments, their tokenized assets are likely to get rejected by U.S. institutional credit markets that now demand strict, modernized collateral eligibility.
  • The July Enforcement Deadline: California’s Digital Financial Assets Law (DFAL) hits full enforcement this July, ending the era of regulatory ambiguity. A documented licensing roadmap is now the baseline for any serious conversation with U.S. capital partners.
  • The Enforceability Paradox: There is a persistent disconnect between “code” and “courtrooms.” U.S. judges increasingly look for “Code-Plus” architecture—smart contracts backed by human-readable legal wrappers that ensure a “meeting of the minds” if a dispute arises.

“This year, the technology is there, but the legal regulatory frameworks are where there may be some opportunity for legal tech firms, and tech firms in general. Many regions, like SEA and Dubai, have groundbreaking technology to really game-change, but the U.S. ‘anchor’ is what is necessary to close deals with U.S. investors,” says Dmitry Shubov, Founder of Dmitry Shubov Consulting.

Navigating the U.S. regulatory landscape can be a bit of a labyrinth, and partnering with a consulting firm can be the best first step to ensure cross-border tech success. Dmitry Shubov Consulting specializes in guiding early-stage SEA legal tech firms into the U.S. market and closing the gap between domestic investors and SEA innovation. For more details on entering the U.S. market as a new legal-tech firm or an established SEA-based legal-tech firm, reach out to Dmitry Shubov Consulting.

About Dmitry Shubov Consulting

At Dmitry Shubov Consulting, our mission is to connect accredited investors with groundbreaking legal technology startups, fostering innovation and growth across Southeast Asia and helping Asian businesses enter the U.S. market. For more information, please visit our website or contact us directly.

Media Contact:

[email protected]


GLOBENEWSWIRE (Distribution ID 9691833)

CORT FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT

NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), of the important April 21, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Corcept common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Corcept class action, go to https://rosenlegal.com/submit-form/?case_id=51868 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 21, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were “powerful support” for the New Drug Application (“NDA”) that Corcept submitted to the U.S. Food and Drug Administration (“FDA”) for this indication. Defendants also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the Class Period, defendants repeatedly told investors that “relacorilant is approaching approval.” In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the relacorilant NDA and, as a result, there was a known material risk that Corcept’s relacorilant NDA would not be approved. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Corcept class action, go to https://rosenlegal.com/submit-form/?case_id=51868 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9687096)